Background: Anticoagulants can prevent thromboembolic activities, improve prognosis, and reduce the mortality rate in Covid-19 patients with coagulopathy. Objective: To analyse the effect of Fondaparinux in decreasing D-dimer levels, and to determine the correlation between patient characteristics, disease severity, and D-dimer levels. Methods: This is a single-centre retrospective cohort study using the medical records of Covid-19 in-patients who were ≥ 17 years old, on Fondaparinux 2.5 mg OD and had D-dimer measurement pre-and post-five days-Fondaparinux therapy during hospitalisation at referral general hospital in Bengkulu, Indonesia between April 2020 and December 2021. The data were assessed to evaluate the differences in the pre-post D-dimer levels, the relationship between patient characteristics and disease severity, and the relationship between disease severity and D-dimer levels. Results: A total of thirty-six patients were included in this study, of which 52.78% were males and 44.44% were aged 46-55 years old. Furthermore, 88.89% had comorbidity, and 55.55% had moderate severity. There was a significant decrease in D-dimer levels in all disease severity (p < 0.05). Patient characteristics and disease severity were not associated with D-dimer depletion (p > 0.05). Conclusion: Fondaparinux reduced the D-dimer levels in all severity of Covid-19 patients.
- Severity level